Recruiting Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma NCT05861050 Conditions Blastoid Variant Mantle Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more Locations City of Hope Medical Center — Duarte, California, United States Mount Sinai School of Medicine — New York, United States Huntsman Cancer Institute — Salt Lake City, Utah, United States View Trial Details
Active, Not Recruiting Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma NCT02427620 Conditions Blastoid Variant Mantle Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
Active, Not Recruiting Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT03946878 Conditions Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, +16 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
